바이오인

No

Date

Investors/

Licensee

Service Provider/

Licensor

Assets

Target·Modality

Indication

Stage

Deal

Value

(USD Mn)

1

8/2

Kyorin Pharmaceutical Co Ltd

EverMed Inc

n/d

(EM-001)

n/d

Respiratory diseases

Preclinical

n/d

2

8/7

Eyenovia Inc

Formosa

Pharmaceuticals

Nanoparticle, Small molecule

(Clobetasol Propionate Ophthalmic

Suspension(0.05%); APP13007)

n/d

Acute Dry Eye

Disease

Approved

n/d

3

8/9

MSD

Curon

Biopharmaceutical

Antibody

(CN201)

CD19xCD3 Bispecific antibody

B-ALL, B-NHL

Phase I/II

1,300

4

8/12

Ocumension

Therapeutics

Alcon

Small molecule

(AR-15512)

TRPM8 agonist

Dry eye

Phase III

130.15

5

8/14

Sun Pharmaceutical

Industries Ltd

Pharmazz Inc

Peptide

(Tyvalzi; Sovateltide)

Cell therapy agonist of the

endothelin B receptor

Cerebral ischemic

stroke

Marketed

15

Small molecule

(Lynfaquin; Centhaquine)

ADRA1 blocker, ADRA2B

stimulator

Hypovolemic shock

Marketed

6

8/20

Dr. Reddy’s

Laboratories;

Aurigene

Pharmaceutical

Services

Kainomyx Inc

n/d

n/d

Malaria

n/d

n/d

7

8/26

CBC Group;

Mubadala

Investment

UCB’s China

Neurology and

Allergy Business

Small molecule(Vimpat; lacosamide)

Small molecule(Keppra; levetiracetam)

Small molecule(Neupro; rotigotine)

Small molecule(Zyrtec; cetirizine)

Small molecule(Xyzal; levocetirizine)

DPYSL2 modulator

SV2A ligand with unknown MoA

DRD1 and DRD2 agonist

HRH1 antagonist

HRH1 inhibitor

Epilepsy

Seizure

PD

Urticaria, Allergy

Allergy

Marketed

680

8

8/28

Neurocrine

Biosciences

Nxera Pharma

(Sosei Group,

Sosei Heptares)

Small molecule

(NBI-1117568)

M4 agonist

Schizophrenia

Phase II

35

No.

Date

Acquires

Issuer

주요 파이프라인

금액
(USD Mn)

1

8/1

Otsuka America Inc

Jnana Therapeutics

JNT-517

Type : Small molecule

Target : SLC6A19

Indication : Phenylketonuria(PKU)

Stage : Phase I/II

1,125

2

8/7

Pharmacosmos Therapeutics Inc

G1 Therapeutics Inc

COSELA

(Trilaciclib)

Type : Small molecule

Target : CDK4, CDK6

Indication : ES-SCLC

Stage : Marketed

405

3

8/8

Recursion Pharma

Exscientia

EXS617

Type : Small molecule

Target : CDK7

Indication : Cancer

Stage : Phase I/II

565

EXS4318

Type : Small molecule

Target : PRKCQ

Indication : Autoimmune disease

Stage : Phase I

Partnership : BMS

4

8/19

Visiox Pharma

Ocuvex Therapeutics

Eybelis;

Omlonti;

Omidenepag

isopropyl

Type : Small molecule

Target : PGE2 receptor

Indication : Glaucoma

Stage : Marketed

n/d

PDP-716

Type : Small molecule

Target : n/d

Indication : Open angle glaucoma

Stage : Phase III

SDN-037

Type : Small molecule

Target : n/d

Indication : Post-surgical inflammation

Stage : Phase III

5

8/22

Rafael Holdings

Cyclo Therapeutics

Trappsol ® Cyclo™

Type : Macrocycle

Target : NPC1

Indication : Niemann-Pick Disease Type C1

Stage : Phase III

22.59